The CoronaVac produced in cooperation with China is the most widely used product in the country. It helps to reduce the death rate of the elderly, but it cannot change uncontrollable conditions.
The Governor of the State of Sao Paulo, Joao Doria, always fancied and under the surveillance of cameras, produced 1.5 million doses of CoronaVac vaccine in cooperation with the Beidantan Medical Research Institute of Sao Paulo on Monday, April 12th. The Sinovac laboratory cooperates. The governor once again showed the photographer Victory V before the vaccine box (the baptized “Brazilian vaccine”).
As the country has experienced a worrying rebound from the epidemic, the political use of vaccines has reached its peak in Brazil. Joao Doria can boast that he is the only state in the league that provides vaccines to the rest of the country: out of ten Brazilians who were vaccinated, eight received the vaccine. “Where is the 400 million doses promised by the federal government to Brazilians?” Today, only the Butantan Institute provides vaccines in Brazil.” Joao Doria recalled President Jair Bolsonaro, who had been destroying vaccinations and slowing down or even destroying vaccine orders.
In early April, the Butantan Institute had produced 39.7 million doses from the 100 million doses ordered by the Ministry of Health. In addition, the federal government’s record is very sluggish: 9.8 million doses of AstraZeneca have been administered, including 5.8 million doses produced by the Fiocruz Medical Research Foundation in collaboration with Oxford University. Fiocruz, under the Ministry of Health, admitted that the 18 million doses of vaccine in preparation (27 million doses in the plan) will be ready by early May.The problem is: delivery delays in China Active ingredients. Even if Pfizer and the Ministry of Health recently signed an agreement to obtain 100 million doses, they will not be able to deliver in Brazil until the second half of this year.
Therefore, most Brazilians will receive the CoronaVac vaccine, which has been less effective against the virus than the messenger RNA vaccine. On January 12, the Butantan Institute presented the Phase 3 conclusions of the test conducted on 9,823 volunteers, all of whom belonged to the medical profession. Then, whether mild or severe, CoronaVac vaccine is effective in 50.38% of cases. This Sunday, a complete study of the Phase 3 results of the test (for more than 12,000 volunteers) has been pre-published in a medical journal. Lancet. The conclusion shows that the efficiency is improved: the efficiency of preventing the onset of symptoms is 50.7%, and people who have not been vaccinated develop severe forms of the disease. In obese people, its effectiveness reaches 75%.
You have 43.69% of the articles to read. The rest only applies to subscribers.